Fertility-sparing treatment for early endometrial cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 45 years old
- Your diagnosis is endometrial cancer that is Grade 1 to 2
- Your scans (MRI or ultrasound) suggest it is limited to the uterus lining or has spread into the uterine muscle less than half
- You strongly want to preserve fertility (future pregnancy)
- You can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a way to treat early-stage endometrial cancer without removing the uterus, so you can still have a chance to carry a pregnancy. It’s for women under 45 with a grade 2 tumor that hasn’t grown into the womb muscle.
This study looks at women with endometrial adenocarcinoma or atypical hyperplasia who had conservative treatment instead of radical surgery. It aims to check how well the treatment works for both cancer and future pregnancy outcomes.
This trial tests whether combining two hormone medicines can treat early endometrial (uterine) cancer while helping preserve the uterus and future fertility. You may be eligible if your cancer is early and limited, with no spread seen on scans, and you can safely take these medicines.
This trial tests a combination of the immunotherapy drug tislelizumab (which helps your immune system fight cancer) with standard chemotherapy, given before surgery for advanced endometrial cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
This trial tests a weight management program for women with early-stage endometrial cancer or atypical hyperplasia who want to keep their fertility. It aims to see if losing weight can improve treatment outcomes.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.